American Pharmaceutical Partners (Schaumburg, Ill) recently received FDA approval for its abbreviated new drug application for carboplatin injection (liquid form) in a 600-mg multidose vial. The product is the generic equivalent of Bristol-Myers Squibb Co's Paraplatin. Carboplatin is indicated for the initial treatment of advanced ovarian carcinoma in combination with other established approved chemotherapeutic agents, as well as for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy. Carboplatin 600 mg is preservative-free and AP-rated. The product vials include a latex-free vial stopper, bar code, and "tall-man" lettering label enhancements to help differentiate carboplatin from other commonly used platinum-based chemotherapies with the same name suffix. The product also is available in 450-mg (liquid and lyophilized), 150-mg (lyophilized), and 50-mg (lyophilized) vials. For more information, visit www.appdrugs.com.
Although the annual HIV diagnosis rate between 2010 and 2014 decreased for black individuals by 16.2%, blacks remain disproportionately affected by HIV/AIDS.
Clinical features with downloadable PDFs